rs727504295
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_005633.4(SOS1):c.1322G>A(p.Cys441Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,358 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
SOS1
NM_005633.4 missense
NM_005633.4 missense
Scores
14
3
1
Clinical Significance
Conservation
PhyloP100: 7.79
Genes affected
SOS1 (HGNC:11187): (SOS Ras/Rac guanine nucleotide exchange factor 1) This gene encodes a protein that is a guanine nucleotide exchange factor for RAS proteins, membrane proteins that bind guanine nucleotides and participate in signal transduction pathways. GTP binding activates and GTP hydrolysis inactivates RAS proteins. The product of this gene may regulate RAS proteins by facilitating the exchange of GTP for GDP. Mutations in this gene are associated with gingival fibromatosis 1 and Noonan syndrome type 4. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
?
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 4 uncertain in NM_005633.4
PM2
?
Very rare variant in population databases, with high coverage;
PP3
?
MetaRNN computational evidence supports a deleterious effect, 0.97
PP5
?
Variant 2-39023106-C-T is Pathogenic according to our data. Variant chr2-39023106-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 40673.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-39023106-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SOS1 | NM_005633.4 | c.1322G>A | p.Cys441Tyr | missense_variant | 10/23 | ENST00000402219.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SOS1 | ENST00000402219.8 | c.1322G>A | p.Cys441Tyr | missense_variant | 10/23 | 1 | NM_005633.4 | A1 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD3 genomes
?
Cov.:
32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461358Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 726978
GnomAD4 exome
AF:
AC:
2
AN:
1461358
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
726978
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 32
GnomAD4 genome
?
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 17, 2023 | Observed in many individuals in published literature with an SOS1-related disorder (Zenker et al., 2007; Pierpont et al., 2010; Lepri et al., 2011; Chinton et al., 2019; Shoji et al., 2019); Not observed at significant frequency in large population cohorts (gnomAD); Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate normal to increased SOS1 activity (Gureasko et al., 2010, Smith et al., 2013); This variant is associated with the following publications: (PMID: 17143282, 24803665, 30417923, 31292302, 31560489, 19077116, 23487764, 17586837, 20186801, 12628188, 21387466, 29493581, 20648242, 34643321, 20133692) - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 19, 2019 | The SOS1 c.1322G>A; p.Cys441Tyr variant (rs727504295) is reported in the literature in multiple individuals affected with Noonan syndrome (Bessis 2019, Ko 2008, Lepri 2011, Pierpont 2010, Tartaglia 2007, Zenker 2007). In at least one affected individual, the variant was not observed in either parent, suggesting a de novo origin (Tartaglia 2007). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The cysteine at amino acid 441 is highly conserved, and while functional studies indicate wildtype activation of pERK (Smith 2013), the variant also exhibits increased PIP2-dependent nucleotide exchange rates (Gureasko 2010). Additionally, other amino acid substitutions at nearby codons (p.Glu433Lys, p.Gly434Arg, p.Ile437Thr) have been reported in individuals with Noonan syndrome and are considered disease-causing (Lepri 2011, Tartaglia 2007, Zenker 2007), suggesting this region is functionally important. Based on available information, the p.Cys441Tyr variant is considered to be pathogenic. References: Bessis et al. Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation. Br J Dermatol. 2019 Jun;180(6):1438-1448. Gureasko J et al. Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3430-5. Ko JM et al. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet. 2008;53(11-12):999-1006. Lepri F et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat. 2011 Jul;32(7):760-72. Pierpont EI et al. Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome. Am J Med Genet A. 2010 Mar;152A(3):591-600. Smith et al. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9. Tartaglia et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007 Jan;39(1):75-9. Zenker M et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet. 2007 Oct;44(10):651-6. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2023 | SOS1: PM6:Strong, PM2, PS4:Moderate, PP3, PP4, PS3:Supporting - |
RASopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 09, 2024 | Variant summary: SOS1 c.1322G>A (p.Cys441Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251002 control chromosomes. c.1322G>A has been reported in the literature in multiple individuals affected with Noonan Syndrome including a de novo occurrence (e.g. Pierpont_2008, Ko_2008, Tartaglia_2007, Alfieri_2008, Lepri_2011, Lee_2011.). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Gureasko_2009). The following publications have been ascertained in the context of this evaluation (PMID: 19077116, 19020799, 17143282, 19568997, 20133692, 21387466, 21784453). ClinVar contains an entry for this variant (Variation ID: 40673). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Aug 06, 2020 | This sequence change replaces cysteine with tyrosine at codon 441 of the SOS1 protein (p.Cys441Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in many individuals affected with Noonan syndrome, including multiple de novo observations (PMID: 20186801, 21387466, 19077116, 17586837, 19020799 17143282, 17586837). ClinVar contains an entry for this variant (Variation ID: 40673). Experimental studies have shown that this missense change induces ERK activation similar to wild type, but increases SOS1 activity in a PIP2-dependent manner (PMID: 23487764, 20133692). For these reasons, this variant has been classified as Pathogenic. - |
Noonan syndrome 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | - | - - |
Noonan syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 20, 2017 | The p.Cys441Tyr variant in SOS1 has been previously identified in six individual s with clinical features of Noonan syndrome, including two confirmed de novo occ urrence (Tartaglia 2007, Zenker 2007, Lepri 2011, Korean Mutation Database, LMM data). This variant has not been identified in large population studies. In summ ary, this variant meets criteria to be classified as pathogenic for autosomal do minant Noonan spectrum disorder based on presence in multiple affected individua ls including de novo occurrences. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;M;.
MutationTaster
Benign
D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D
Sift4G
Pathogenic
D;D;D
Polyphen
D;D;.
Vest4
MutPred
Loss of catalytic residue at M446 (P = 0.0424);Loss of catalytic residue at M446 (P = 0.0424);Loss of catalytic residue at M446 (P = 0.0424);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at